Analytical Data
-
Gene name
Cxcl14
- Application
-
Alternative Names
B-cell and monocyte-activating chemokineChemokine BRAKKidney-expressed chemokine CXCMIP-2GSmall-inducible cytokine B14
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9WUQ5
-
Expression Region
23-99aa
-
Molecular Weight
13.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cxcl14, also known as chemokine (CXC motif) ligand 14, is a member of the chemokine family that has garnered significant interest in the field of immunology and cancer research. Initially identified for its role in immune cell trafficking, Cxcl14 is now recognized for its multifaceted functions, including modulation of tumor microenvironments and participation in inflammatory responses. Its expression is predominantly observed in various tissues, and notably, it is often downregulated in several types of cancers, suggesting a potential tumor suppressor role. Research has indicated that Cxcl14 can influence the behavior of not only immune cells but also cancer cells, affecting processes such as migration, proliferation, and apoptosis. The recombinant protein form of Cxcl14 is being extensively explored for its therapeutic potential, including its ability to inhibit tumor growth and enhance anti-tumor immunity. Additionally, understanding the signaling pathways driven by Cxcl14 may unveil new targets for cancer therapy and immunomodulation. Despite its promise, further exploration is needed to fully elucidate the mechanisms of action and develop effective applications in clinical settings. Overall, the study of Cxcl14 and its recombinant protein represents a vital area of research with implications for improving cancer treatment strategies and understanding immune system interactions.
